# Impel Healthcare Catalysts

Impel Healthcare Catalysts is a Private Equity based in Manchester, United Kingdom.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Manchester, United Kingdom
- **Region:** Europe
- **Address:** Manchester, United Kingdom
- **Assets under management:** Undisclosed
- **Website:** www.impelhealthcare.co.uk
- **LinkedIn:** https://www.linkedin.com/company/impel-healthcare-catalysts

## Regulatory record

- **Reports private funds:** No

## About

Impel Healthcare Catalysts is a UK-focused growth capital investor. They have made one investment to date. Their most recent investment was in Trio Ostomy Care via Private Equity on October 28, 2019.

## Sectors

- Healthcare Services
- Digital Health
- Pharmaceuticals & Biotech
- Medical Devices

## Questions

### What is Impel Healthcare Catalysts' investment strategy?

Impel targets growth-stage healthcare companies across services, digital health, medical devices, and specialty pharma. The firm prioritizes ventures where regulatory approval, clinical validation, and reimbursement coding are the primary commercial gating factors. It structures direct equity investments and works alongside management teams to accelerate market access within centralized health systems.

### Which geographies does Impel Healthcare Catalysts cover?

The firm concentrates on the United Kingdom and Ireland, with additional activity in the Benelux region. Its Manchester base positions it to source deals across NHS-integrated markets and European health systems where procurement and formulary decisions drive adoption.

### Does Impel participate in fund commitments or only direct deals?

Impel structures direct equity investments in portfolio companies rather than operating as a fund-of-funds. The firm engages in syndicated rounds where co-investors bring complementary clinical or regulatory capabilities.

### How does Impel source its healthcare investments?

Origination flows through relationships with NHS trusts, private hospital groups, clinical key opinion leaders, and health insurers. The firm's network within the UK health ecosystem provides early visibility into ventures navigating regulatory and reimbursement pathways.

### What sectors does Impel explicitly avoid?

Impel does not pursue pure technology plays without a clinical or care-delivery anchor. Consumer wellness apps, unregulated health-tracking tools, and ventures lacking a defined reimbursement or formulary pathway fall outside the mandate. The firm also avoids preclinical-stage biotech where regulatory timelines exceed its growth-equity horizon.

## Related profiles

- [Impel Capital](https://altss.com/profile/impel-capital)
- [Impellent Ventures](https://altss.com/profile/impellent-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/impel-healthcare-catalysts

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology